IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026 REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) ( ...